Sunitinib molecular targeted therapy. Medical search. Frequent questions

Mutational assessment is important because of the availability of specific, molecular-targeted therapy with KIT / PDGFRA tyrosine kinase inhibitors (TKIs) (eg, imatinib, sunitinib). (arupconsult.com)
Imatinib resistance, either primary or secondary, is associated with specific tumor genotypes, so genotyping of individual patient tumors helps guide decisions concerning whether to offer imatinib and at what dose, or whether an alternative tyrosine kinase inhibitor (TKI) (ie, sunitinib) is more appropriate. (arupconsult.com)
The US Food and Drug Administration (FDA) recently approved sunitinib malate (Sutent) capsules for two types of cancer: advanced renal cell carcinoma and malignant gastrointestinal stromal tumor (GIST), after disease progression on or intolerance to the frontline drug imatinib mesylate (Gleevec). (cancernetwork.com)
At the recent American Society of Clinical Oncology (ASCO) 2006 Gastrointestinal Cancers Symposium in San Francisco, researchers from Dana-Farber Cancer Institute in Boston reported on a phase III clinical trial in which sunitinib was given to control GIST in patients whose tumors had become resistant to imatinib. (cancernetwork.com)
In the study, the research team led by Dr. Demetri compared overall survival and duration of tumor control in two groups of imatinib-resistant GIST patients-207 received sunitinib, and 105 received a placebo. (cancernetwork.com)
The benefits of sunitinib held steady regardless of the dose or duration of imatinib therapy that patients previously had received. (cancernetwork.com)
After progression from imatinib, approved options include Sunitinib, and more recently Regorafenib. (shyamhemoncclinic.com)
Surgical removal of the tumor is a common approach, sometimes accompanied by targeted therapy with drugs that specifically target the molecular abnormalities found in GIST cells, such as imatinib (Gleevec) or sunitinib (Sutent). (gokhanakbulut.com)
However, resistance to imatinib is a growing problem and other targeted therapeutics such as sunitinib are available. (elsevierpure.com)
Cytogenetic and molecular genetic findings were integrated and correlated with clinico-pathological parameters, including imatinib/sunitinib therapy response. (biomedcentral.com)
Imatinib, an oral targeted therapy, has been available in Benin since 2010 and free since 2016. (biomedcentral.com)
Aberrant platelet-derived growth factor receptor beta (PDGFRβ) signaling in cancer has motivated the development of several antagonists currently in clinical use, including imatinib, sunitinib, and sorafenib. (lu.se)

The VEGF-R inhibitors (vascular endothelial growth factor receptor) like bevacizumab showed that the antiangiogenic therapy combined with radiation and chemotherapy improved disease free survival and overall survival in locally advanced head and neck cancers without bleeding complications. (yourhealthmagazine.net)
Other novel targeted treatments are in clinical evaluation, including antiangiogenic compounds (Bevacizumab, sunitinib, vatalanib, and others) and bi-functional drugs such as lapatinib (anti Her-2 and EGFR agent) showing promising activity. (eurekaselect.com)
11 Monoclonal antibodies, including bevacizumab, target VEGFR or VEGFR2. (decisionsindentistry.com)
Novel therapies targeting angiogenesis, such as bevacizumab and sunitinib, are showing promise in NETs by improving progressionfree survival alone or in combination with mTOR inhibitors. (elsevierpure.com)
Although the optimal treatment strategy continues to evolve, three agents that target angiogenesis (sunitinib, bevacizumab, and pazopanib) and a mammalian target of rapamycin (mTOR)-targeted therapy (temsirolimus) have been approved as front-line agents. (medscape.com)

Novel therapies for head and neck cancer include agents that target the HER family, PARP, AKT pathway, SRC-family, MET and COX pathways as well as therapies that specifically target angiogenesis. (yourhealthmagazine.net)
In addition to confirming the safety and efficacy of sunitinib, the findings illustrated that therapies targeting several signaling pathways inside cancer cells may be an effective treatment approach that may also be applicable to other difficult-to-treat cancers, including kidney cancer. (cancernetwork.com)
The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. (oncotarget.com)
2 However, even these new target drugs have been shown to have a cardiotoxic potential, especially when used as combination therapies, by inhibition of transduction pathways in normal or non-cancerous cells. (touchoncology.com)
Thus, the simultaneously application of cisplatin with other anticancer drugs that target new signalling pathways has been investigated [ 7 ]. (hindawi.com)
The recognition of molecular pathways involved in the pheochromocytoma and paraganglioma tumorigenesis has driven the development of new therapeutic options. (thieme-connect.com)
There have been major developments in our understanding of the histopathological classification, genetics, molecular signaling pathways, and treatment of neuroendocrine tumors (NETs) over the last decade. (elsevierpure.com)
Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. (ijpbs.net)
Epidermal growth factor receptor (EGFR) inhibitors are part of an emerging class of anticancer medicines known as "targeted therapy," which target pathways more specific to neoplastic proliferation than traditional chemotherapeutic agents. (medscape.com)
in contrast, EGFR inhibitors (EGFRIs) target pathways more specific to survival of neoplastic cells, thus belonging to a new class of chemotherapeutic agents - so-called "targeted therapy. (medscape.com)

These findings support the hypothesis that the possibility should be considered of sunitinib increasing breast CSCs though it inhibits TNBC tumor angiogenesis and growth/progression, and that effects of sunitinib on Notch expression and hypoxia may increase breast cancer stem cells. (biomedcentral.com)
This work provides the groundwork for an innovative therapeutic strategy in TNBC therapy by using sunitinib plus γ-secretase inhibitor to simultaneously target angiogenesis and CSC. (biomedcentral.com)
Recently, with the advent of immunotherapy and anti-angiogenesis therapy, the survival of RCC patients has been improved[ 4 ]. (medsci.org)

Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients who received the targeted therapy sunitinib (Sutent), regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group, according to new analysis of the CheckMate-214 clinical trial. (news-medical.net)

The aim of this paper is to analyse sunitinib malate in vitro ability to enhance cisplatin cytotoxicity in T24, 5637, and HT1376 human urinary bladder-cancer cell lines. (hindawi.com)
A cell cycle arrest in early S-phase and in G 0 /G 1 -phase was also found after exposure to cisplatin and sunitinib malate, in isolation, respectively. (hindawi.com)
Sunitinib malate is an orally bioavailable molecule with the ability to block the intracellular tyrosine kinase domain of tyrosine kinase receptors. (hindawi.com)
Nonetheless, there is a scarce of data available about the combination of sunitinib malate and cisplatin on urinary bladder cancer. (hindawi.com)
This investigation aims to analyse the in vitro effects of cisplatin and sunitinib malate in isolation and in combination, on one human nonmuscle invasive urinary bladder-cancer cell line (5637) and on two human muscle-invasive urinary bladder-cancer cell lines (T24 and HT1376). (hindawi.com)
Sunitinib malate is approved by the Food and Drug Administration (FDA) to treat a type of stomach cancer called gastrointestinal stromal tumor (GIST). (news-medical.net)

What is the role of mutational analysis in determining therapy for gastrointestinal stromal tumors? (arupconsult.com)
These findings are highly significant because they show sunitinib can control tumors and improve survival rates of patients with this condition. (cancernetwork.com)
Radiation therapy may provide palliative relief from symptomatic metastases, control recurrent tumors, and prevent recurrence of advanced resected tumors. (medscape.com)
The situation with solid tumors is considerably more complex, and the evolution of targeted therapies for these cancers is still in its infancy. (cancernetwork.com)
At present, and for some years to come, the treatment of most solid tumors will continue to rely on a patchwork of empirically derived and newly introduced molecularly targeted agents. (cancernetwork.com)
Whereas oncogenic KIT or PDGFRA mutations seem vital to promote the neoplastic transformation, additional somatic alterations are presumably necessary for the biological and clinical progression of these tumors and may explain the different responses to targeted therapy seen in these patients. (biomedcentral.com)
In the Nature study, researchers compared the two drugs head to head and found that the HIF-2 inhibitor was more active than sunitinib and that it was active against tumors progressing on sunitinib. (eurekalert.org)
Researchers surprisingly found a subset of tumors that do not respond to the drug, but were able to identify biomarkers that, once verified, would help determine which patients are more likely to benefit from HIF-2 therapies. (eurekalert.org)
Therefore, a high detection rate of mutations in HLRCC families may enable early identification of at-risk individuals and allow early initiation of therapy while their tumors are still small. (biomedcentral.com)

Sunitinib has been used as anticancer treatments in several tumor types including breast cancer [ 19 ], however clinical observations indicate this therapy may have limited efficacy. (biomedcentral.com)
TIME-related RNA or RNA regulators could be promising targets for anticancer immunotherapy. (biomedcentral.com)
The complex interplay between cancer cells and the TIME influences the outcome of immunotherapy and other anticancer therapy (Fig. 1 ). (biomedcentral.com)
Combination of sunitinib and PD-L1 blockade enhances anticancer efficacy of TLR7/8 agonist-based nanovaccine. (ku.edu)
P90 ribosomal S6 kinases: A bona fide target for novel targeted anticancer therapies? (lu.se)

Sorafenib and sunitinib are multikinase inhibitors that target the intracellular activity of VEGF-R. These drugs have shown very promising activity in Phase I and II trials for head and neck cancers. (yourhealthmagazine.net)
Currently sorafenib and sunitinib are in phase III trials, the great advantage of these drugs for patients is that they are in a pill form and are very well tolerated by people of all ages. (yourhealthmagazine.net)
The cardiotoxic effects of sorafenib and sunitinib may cause hypertension, left ventricular ejection fraction (LVEF) dysfunction and/or congestive heart failure (CHF), and arterial thrombo-embolic events (ATE). (biomedcentral.com)

Sunitinib is the first molecularly targeted therapy proven to work against a cancer after another targeted therapy has failed," said the study's principal investigator, George Demetri, md, director of the Center for Sarcoma and Bone Oncology at Dana-Farber and associate professor of medicine at Harvard Medical School. (cancernetwork.com)
Here we summarise the current status and future developments of molecularly targeted therapies in GC and GEJ cancer. (docksci.com)
Molecularly targeted therapy based on tumor molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomized, controlled phase 2 trial. (ijpbs.net)

Originally called SU11248, sunitinib is an oral therapy belonging to a new class of multikinase inhibitors that attack cancer by inhibiting both tumor growth and blood supply. (cancernetwork.com)
Small molecular inhibitors of VEGF tyrosine kinase activity, such as sorafenib, appear promising. (biomedcentral.com)
While, the role of sunitinib and inhibitors of mammalian target of rapamycin (mTOR) in breast cancer has to be defined. (biomedcentral.com)
This review focusses on clinical aspects of treatment of breast cancer with monoclonal antibodies, and tyrosine kinase and mammalian target of rapamycin (mTOR) inhibitors. (biomedcentral.com)
DALLAS - September 05, 2016 -A new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer, researchers with the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center have found. (eurekalert.org)
We want to make HIF-2 inhibitors available to patients and are currently carrying out clinical trials," said Dr. James Brugarolas, Director of the Kidney Cancer Program, who is leading an $11 million SPORE grant from the National Cancer Institute seeking to translate new discoveries into novel therapies for kidney cancer patients. (eurekalert.org)
Cowden syndrome associated renal cell carcinoma patients could benefit from mTOR and anti VEGF therapy, and potentially also by tyrosine kinase inhibitors. (sgo-iasgo.com)
Her laboratory is currently investigating the role of cytochromes P450 in the metabolism and hepatotoxicity of tyrosine kinase inhibitors used in targeted cancer therapy. (unc.edu)
Our laboratory is currently investigating the influence of individual variations in cytochrome P450 and UDP-glucuronosyltransferase enzymes on the metabolism and hepatotoxicity of tyrosine kinase inhibitors used in cancer therapy as well as the natural product cannabidiol used in epilepsy treatment. (unc.edu)

Although GIST is relatively uncommon, our understanding of it at the molecular level-down to specific mutations in DNA-has made this disease a proving ground for new therapies that could be useful for treating other cancers. (cancernetwork.com)
Since then, more targeted therapies are available to treat GIST. (shyamhemoncclinic.com)

At present, several antiangiogenic therapies are in clinical trials testing their promise in breast cancer. (biomedcentral.com)
Consequently, this review (which is being presented in two parts) consists of a perspective on current opportunities and the "work in progress" and is not a compendium of clinical trials with novel targeted agents still seeking an indication. (cancernetwork.com)
Dr. Marlana Orloff gives an update on targeted therapies currently being studied in clinical trials. (slideshare.net)
There are an unprecedented number of ongoing clinical trials of innovative treatments for this disease, and the development of combination therapy will lead to better therapeutic outcomes. (elsevierpure.com)
In recent years, clinical trials have established targeted therapy as the first-line treatment in patients with metastatic disease. (medscape.com)

As sometimes happens in patients, mice on sunitinib were sickly and lost weight, whereas mice on the HIF-2 inhibitor gained weight while on the study," he said. (eurekalert.org)
The recent success of everolimus, an inhibitor of the mammalian target of rapamycin, is proof of principle that targeting this pathway will lead to improved outcomes in these patients. (elsevierpure.com)

However, therapy of adjuvant/metastatic disease is still palliative with a very low probability to induce complete remission and definitive cure of disease. (eurekaselect.com)
Parathyroid carcinoma (PC) is a rare endocrine malignancy with no approved systemic therapies for unresectable locally invasive or distant metastatic disease. (cancerindex.org)
No history of radiation therapy to the jaws or metastatic disease to the jaws. (decisionsindentistry.com)
Targeted therapy and immunomodulatory agents are considered standard of care in patients with metastatic disease. (medscape.com)

Current therapeutic strategies for GISTs revolve around targeted therapy against PDGFRA , KIT , and related receptor tyrosine kinases. (arupconsult.com)
Trastuzumab is a humanised monoclonal antibody against the human epidermal growth factor receptor (HER2), a tyrosine kinase receptor overexpressed at the time of diagnosis in 15 % of breast cancer (BC) and up to 20-30 % of metastatic BC, 4 which is associated with more aggressive disease, poor response to therapy and survival. (touchoncology.com)

The first randomized study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months. (news-medical.net)

Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial. (news-medical.net)

The relevant efforts of basic research to identify the key and selective molecular alterations, which sustain breast cancer growth and progression allowed the possibility to develop specific molecular target treatments. (eurekaselect.com)
The cellular and molecular nature of the TIME influences cancer progression and metastasis by altering the ratio of immune- suppressive versus cytotoxic responses in the vicinity of the tumor. (biomedcentral.com)
Yang Q, Guo N, Zhou Y, Chen J, Wei Q, Han M. The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advances in targeted therapy. (ijpbs.net)

There have been no randomized trials of sunitinib demonstrating clinical benefit such as increased survival or improvement in disease-related symptoms in renal cell carcinoma patients. (cancernetwork.com)
This disease has peculiarities in its etiopathogenesis, presentation, risk of nodal and distant metastasis, response to therapy and overall survival (OS) outcomes that stand out as compared to other head and neck cancer subsites. (intechopen.com)
Jillard et al reported that post-thyroidectomy 131 I therapy improves survival in patients with Hürthle cell carcinoma. (medscape.com)
The development of effective adjuvant therapy based on postoperative administration of short-term chemotherapy (4-6 months) or long-term hormone therapy (5 years) or both, significantly improved survival of patients. (eurekaselect.com)
TNBCs exhibit a high level of molecular heterogeneity, and are biologically aggressive: a poor prognostic factor for disease-free and overall survival in the adjuvant and neoadjuvant setting, a more aggressive clinical course in the metastatic setting, and no effective specific targeted therapy [ 1 , 2 ]. (biomedcentral.com)
Systemic therapy for metastatic PSCC yields poor outcomes, with a median overall survival (OS) of 6 to 9 months [ 1 - 10 ]. (oncotarget.com)
The delicate balance between effective cancer therapy and the risk of secondary cardiovascular disease that could affect the gain of survival, requires a profound collaboration between oncologists and cardiologists, with the aim of creating a personalised therapy for the patient and their illness. (touchoncology.com)
ADR: IPSEY) today announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx® (cabozantinib) in combination with nivolumab provides survival and response rate benefits after three-years in the first-line treatment of advanced renal cell carcinoma (aRCC), compared to sunitinib. (news-medical.net)

Not only has knowledge of the genomic landscape helped inform the development of new drugs, this understanding also promises to improve risk stratification of tumours and to determine their sensitivity to systemic therapies. (springer.com)

TKIs, such as sunitinib and sorafenib, inhibit phosphorylation of receptors involved with vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor. (decisionsindentistry.com)

Ongoing trials are currently testing the efficacy of drugs that target the M-TOR pathway like temsirolimus which appear to have a synergistic effect when used in combination with radiation or chemotherapy. (yourhealthmagazine.net)

Second, 131 I therapy may destroy occult microscopic carcinoma. (medscape.com)
thus, radioactive iodide treatment, which is the most useful nonsurgical therapy for recurrent well-differentiated thyroid carcinoma, is not always useful in patients with Hürthle cell carcinoma. (medscape.com)
[ 35 , 36 ] Retinoic acid therapy also may be considered in patients with Hürthle cell carcinoma that does not take up radioactive iodide, although this is not yet a standard form of therapy. (medscape.com)
Penile squamous cell carcinoma (PSCC) is an orphan malignancy with poorly understood biology and suboptimal systemic therapy. (oncotarget.com)
The goal of this clinical research study is to compare the safety and effectiveness of cabozantinib and sunitinib when given to patients with metastatic (has spread) variant histology renal cell carcinoma (vhRCC), a type of kidney cancer. (mycancergenome.org)
Kitamura N, Sento S, Yoshizawa Y, Sasabe E, Kudo Y, Yamamoto T. Current trends and prospects of molecular targeted therapy in head and neck squamous cell carcinoma. (ijpbs.net)
Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma. (cdc.gov)

In fact, we shall focus on integrating emerging treatments with therapeutic strategies that include both the older endocrine therapies (the "original targeted therapies") against breast and prostate cancers, and the empirically-derived successful chemotherapies, such as platinums, that are used in gynecologic cancers. (cancernetwork.com)
Identification of molecular pathway resulting in pituitary tumorigenesis remains challenges in endocrine oncology. (cancerindex.org)

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a promising target for well-differentiated NETs. (elsevierpure.com)

However, prospective identification of targets in the clinic will not only illuminate their clinical significance, but will also further accelerate drug development-witness the way in which the introduction of gefitinib (Iressa) for lung cancer was followed in less than a decade by the identification of driver mutations, new targeted drugs, and the universal adoption of molecular profiling for treatment selection. (cancernetwork.com)
GISTs, the analysis of GISTs became much more accurate through the use of immunohistochemical (IHC) -panel (Compact disc117/Pup1) and molecular evaluation (mutations, as well as the breakthrough of the foundation of GISTs [1,2]. (mycareerpeer.com)
The findings of KIT and ICCs, proto-oncogene mutations and CD117 expression were identified in most GISTs, which opened a order SKI-606 new era of molecular analysis in GISTs. (mycareerpeer.com)

In the study in Nature, investigators show that HIF-2 inhibition was able to control metastatic kidney cancer even after 7 lines of prior therapy. (eurekalert.org)
The findings show that HIF-2 is a promising target to combat kidney cancer, said Dr. Brugarolas, senior author and a Virginia Murchison Linthicum Scholar in Medical Research at UT Southwestern. (eurekalert.org)
We successfully treated the patient with locally advanced HLRCC-associated kidney cancer, who has received active surveillance because of at-risk individual, by radical nephrectomy and extended retroperitoneal lymph node dissection, and examined surgically resected samples from a molecular point of view. (biomedcentral.com)
Furthermore, to our knowledge, there have been no case reports of the patients of at-risk of HLRCC-associated with kidney cancer who received active surveillance and were treated successfully, and little is known about the relationship between the clinicopathological features and molecular changes associated with targeting therapy in this disease. (biomedcentral.com)
A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need. (news-medical.net)
Cabozantinib and sunitinib are both FDA approved and commercially available for the treatment of advanced kidney cancer, including vhRCC. (mycancergenome.org)

On the other hand, the looming genomic data for nasopharyngeal cancer aid in the development of powerful biomarkers and promising targeted therapy. (hkmj.org)
Consequently, the molecular and genetic biomarkers provide additional information for the analysis of GISTs. (mycareerpeer.com)
Traditional chemotherapy and radiotherapy have limited effect in RCC, and molecular biomarkers are more targetable to guide treatment decisions. (medsci.org)

Clinically, cellular adaptations to VEGF-targeted anti-angiogenic therapy might induce drug resistance in RCC after transient disease stabilization, which limits the therapeutic efficacy of this approach and has been the major problem for this treatment. (biomedcentral.com)

Antineoplastic therapy is frequently complicated by the development of cardiotoxicity, either as the direct effects of chemotherapy on the heart, such as left ventricular dysfunction (LVD), heart failure (HF) or ischaemia, or as indirect effects due to haemodynamic changes, thrombotic events or hypertension. (touchoncology.com)
Current therapies include surgery, systemic chemotherapy and radiopharmaceutical agents. (thieme-connect.com)
These targeted therapies are usually associated with fewer systemic side effects than standard chemotherapy. (medscape.com)

There are also combination therapies that affect multiple receptors such as lapatinib (approved for human epidermal growth factor receptor 2-positive [HER2+] breast cancer) and afatinib (approved for non-small cell lung cancer), which inhibit both the EGFR and HER2 receptors, and vandetanib (approved for advanced medullary thyroid cancer), which inhibits EGFR, vascular endothelial growth factor (VEGFR), and rearranged during transfection (RET) activities. (medscape.com)

The important interplay between the molecular genetics of gastrontestinal stromal tumour and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumours. (elsevierpure.com)

Targeted therapy" is becoming the centerpiece of current therapeutic strategies, and is often mentioned as the desirable direction for future progress. (cancernetwork.com)
To summarize, multiplatform comprehensive analysis of kinases discovered potential drivers of PSCC and actionable therapeutic targets. (oncotarget.com)

In mTOR Inhibition for Cancer Therapy: Past, Present and Future (pp. 93-112). (elsevierpure.com)

For each cancer discussed in the first part of our overview, as well as in Part II, which will deal with more common cancers, we briefly cover the tumor biology, how targeting was achieved, the introduction of immune modulation or immune-conjugates, and the impact these therapies are having in the disease. (cancernetwork.com)
With the understanding of the molecular biology of GISTs and the finding of effective targeted therapy against KIT, GISTs became more important than before, and the nature of the disease becomes chronic. (mycareerpeer.com)
Cancer Systems Biology and Epidemiology: Target Identification, Combination Therapy, and Personalized Treatment in Cancer Medicine. (ijpbs.net)

Rejhová A, Opattová A, ?umová A, Slíva D, Vodi?ka P. Natural compounds and combination therapy in colorectal cancer treatment. (ijpbs.net)

In contrast, monoclonal antibodies that target EGFR, such as cetuximab and panitumumab, bind to its extracellular domain and competitively inhibit endogenous ligand binding to the receptor. (medscape.com)

However, as these therapies are only palliative, patients' quality of life and personal preferences should always be considered. (thieme-connect.com)
MDT decision was for further palliative radiotherapy and therapy with zoledronate for symptomatic relief. (biomedcentral.com)

The time that elapsed before tumor growth was more than four times longer in the sunitinib group (27.3 weeks) than in the placebo group (6.4 weeks). (cancernetwork.com)

This is a classic example of how knowledge of pathophysiology, especially at molecular/genetic level can help decide treatment. (shyamhemoncclinic.com)
Developing a culturally targeted video to enhance the use of genetic counseling in Latina women at increased risk for hereditary breast and ovarian cancer. (cdc.gov)
Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small-Cell Lung Cancer. (cdc.gov)

MDA-MB-468 cells were exposed to sunitinib for 18 hours for measuring proliferation (3H-thymidine incorporation), migration (BD Invasion Chamber), and apoptosis (ApopTag and ApoScreen Anuexin V Kit). (biomedcentral.com)
Sunitinib significantly inhibited the proliferation, invasion, and apoptosis resistance in cultured basal like breast cancer cells. (biomedcentral.com)

Understanding the differential behavior of regulatory networks during health, disease, and in response to drugs is crucial for enhancing drug development efforts, identifying new targets, delineating off-target effects, predicting disease, developing combinatorial drug regimens, and developing personalized treatments targeted at the molecular level. (ijpbs.net)

Hypertension is a common side effect from antiangiogenic therapy. (yourhealthmagazine.net)

Trastuzumab, a humanized monoclonal antibody to HER-2, is the first molecular targeting agent approved for therapy of metastatic breast cancer, capable to significantly improve clinical outcome in combination with cytotoxic therapy. (eurekaselect.com)

A 48-year-old woman with a left renal tumor and involvement of multiple regional lymph nodes with high accumulation of fluorine-18-deoxyglucose on positron emission tomography was treated with axitinib as a neoadjuvant therapy. (biomedcentral.com)
Correlation with outcome needs to be more comprehensively furnished, particularly for small renal masses, rarer non-clear cell renal cancers, and for all tumours undergoing targeted therapy. (springer.com)

Traditionally, proteins like HIF-2 were disregarded as drug targets because their shape made it nearly impossible to design drugs against them," Dr. Brugarolas said. (eurekalert.org)
The following article summarises the recent data in the literature on the epidemiology and pathophysiology of cardiotoxicity induced by different target drugs, as well as strategies for patient management before, during and after antineoplastic treatment, early diagnosis of cardiovascular adverse events, with particular attention on the role of echocardiography. (touchoncology.com)
Opening the debate was Giuseppe Curigliano, MD, PhD, director of new drugs and early drug development for the Innovative Therapies Division at the European Institute of Oncology, Milan, Italy, who argued the case that HER2 low is a separate clinical entity. (medscape.com)

The adequacy of therapy is monitored by measuring serum TSH about 8-12 weeks after the treatment begins. (medscape.com)
In this context, several members of our group have been trying to understand molecular pathogenesis, leading to improvements in the treatment of HCC. (biomedcentral.com)
Diagnosis and treatment are challenging in low-income countries due to relatively poor access to immunohistochemistry and targeted therapy. (biomedcentral.com)
Current or previous treatment with antiresorptive therapy alone or in combination with immune modulators or antiangiogenic medications. (decisionsindentistry.com)

Applied Immunohistochemistry and Molecular Morphology. (elsevierpure.com)

Intratumoral heterogeneity is an inherent feature of most human cancers and has profound implications for cancer therapy. (lu.se)

To even more assistance our findings, a latest review demonstrated that the E3 ubiquitin Ligase IDOL targets the VLDLR receptor for degradation, especially via the lysine residues adjacent to the NPXY motif. (micrornasynthesis.com)

Sunitinib-treated patients also had a 50% reduction in the relative risk of death compared to their counterparts. (cancernetwork.com)
Sunitinib was generally well tolerated, with side effects such as mild to moderate fatigue, diarrhea, nausea, mouth sores, and skin discoloration, which rarely interfered with the patients' ability to continue taking the drug. (cancernetwork.com)
The results were so striking, even at the first interim data analysis, that the independent data-monitoring committee recommended that patients initially assigned to the placebo group be allowed to take sunitinib, said Dr. Demetri. (cancernetwork.com)
Most patients can be observed without any specific therapy for a long time. (shyamhemoncclinic.com)
however, 27 % of patients who received the combination therapy developed signs of HF (16 % were in New York Heart Association [NYHA] class III-IV). (touchoncology.com)
11 patients with advanced PC were selected to undergo molecular testing. (cancerindex.org)
Surgery is often a preferred therapy because it may cure or allow a long-term remission in patients with locoregional or isolated resectable distant metastases. (thieme-connect.com)
Not only can these toxicities severely affect patients' quality of life, but in some specific instances, they can be associated with increased response to therapy. (medscape.com)

This review provides an updated overview of the status of development of targeted therapy in breast cancer, as well as the challenges related to the rational use of molecular targeting agents. (eurekaselect.com)

This diagnosis became very prominent due to widespread HIV infection, however the incidence and mortality has significantly reduced after introduction of active antiretroviral therapy (HAART). (shyamhemoncclinic.com)
The xenograft models showed that oral sunitinib significantly reduced the tumor volume of TNBCs in association with the inhibition of tumor angiogeneisis, but increased breast CSCs. (biomedcentral.com)

TNBCs comprise the basal and claudin-low molecular subtypes. (biomedcentral.com)

In 1997, UT Southwestern researchers Dr. Steven McKnight, Chairman of Biochemistry, and molecular geneticist Dr. David Russell, Vice Provost and Dean of Basic Research, led research discovering and describing the protein encoded by the EPAS1 gene, also known as HIF-2α, the main HIF-2 component. (eurekalert.org)

Understanding the usefulness of careful cardiovascular monitoring might be important for the prevention of fatal cardiovascular events, and to avoid discontinuation of therapy for the underlying cancer. (biomedcentral.com)
However, cutaneous side effects can result in decreased quality of life and may cause interruption or discontinuation of therapy despite effectiveness. (medscape.com)

True impact of molecular pathology. (shyamhemoncclinic.com)

Anatomy8

Organisms3

Diseases48

Chemicals and Drugs68

Analytical, Diagnostic and Therapeutic Techniques and Equipment52

Phenomena and Processes21

Disciplines and Occupations1

Anthropology, Education, Sociology and Social Phenomena3

Technology, Industry, Agriculture1

Humanities1

Information Science2

Health Care20

Imatinib12

Bevacizumab5

Pathways10

Angiogenesis3

Sutent1

Malate6

Tumors9

Anticancer5

Sorafenib and sunitinib3

Molecularly3

Inhibitors9

GIST2

Clinical trials5

Inhibitor2

Metastatic disease4

Tyrosine2

Pheochromocytoma and paraganglioma1

Immunotherapy1

Progression3

Survival8

Systemic therapies1

TKIs1

Temsirolimus1

Carcinoma7

Endocrine2

Mammalian1

Mutations3

Kidney cancer6

Biomarkers3

Efficacy1

Chemotherapy3

Combination therapies1

Therapeutics1

Therapeutic2

MTOR1

Biology3

Compounds1

Monoclonal antibodies1

Palliative2

Tumor growth1

Genetic3

Apoptosis2

Treatments1

Hypertension1

Trastuzumab1

Renal2

Drugs3

Treatment4

Immunohistochemistry1

Cancers1

Receptor1

Patients8

Breast cancer1

Significantly reduced2

Subtypes1

Biochemistry1

Discontinuation of therapy2

Pathology1